ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 132 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.88 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $246 | -87.4% | 22 | -75.8% | 0.00% | – |
| Q2 2023 | $1,947 | +337.5% | 91 | +727.3% | 0.00% | – |
| Q1 2023 | $445 | -75.5% | 11 | -71.8% | 0.00% | – |
| Q4 2022 | $1,814 | +81.4% | 39 | +200.0% | 0.00% | – |
| Q3 2022 | $1,000 | 0.0% | 13 | 0.0% | 0.00% | – |
| Q2 2022 | $1,000 | -83.3% | 13 | -84.9% | 0.00% | -100.0% |
| Q1 2022 | $6,000 | +500.0% | 86 | +561.5% | 0.00% | – |
| Q4 2021 | $1,000 | 0.0% | 13 | 0.0% | 0.00% | – |
| Q3 2021 | $1,000 | 0.0% | 13 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | 0.0% | 13 | 0.0% | 0.00% | – |
| Q1 2021 | $1,000 | 0.0% | 13 | 0.0% | 0.00% | – |
| Q4 2020 | $1,000 | 0.0% | 13 | -45.8% | 0.00% | – |
| Q3 2020 | $1,000 | -66.7% | 24 | -54.7% | 0.00% | -100.0% |
| Q2 2020 | $3,000 | +50.0% | 53 | +60.6% | 0.00% | 0.0% |
| Q1 2020 | $2,000 | – | 33 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 511,186 | $43,686,000 | 11.23% |
| GREAT POINT PARTNERS LLC | 210,400 | $17,981,000 | 2.80% |
| ARMISTICE CAPITAL, LLC | 456,000 | $38,970,000 | 2.34% |
| Matarin Capital Management, LLC | 210,208 | $17,964,376,000 | 1.16% |
| Sapphire Star Partners LP | 8,168 | $698,000 | 0.70% |
| Granahan Investment Management | 103,320 | $8,830,000 | 0.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 867,500 | $74,137,000 | 0.44% |
| 361 CAPITAL LLC | 19,040 | $1,627,000 | 0.35% |
| ALGERT GLOBAL LLC | 17,922 | $1,532,000 | 0.33% |
| AlphaMark Advisors, LLC | 9,310 | $796,000 | 0.32% |